NCT06208878 is an observational long-term follow-up (up to 15 years) of patients previously treated with allogeneic CRISPR-edited CAR T-cell therapies for hematologic or solid malignancies. No active intervention is administered, the study assesses long-term safety and efficacy. Intervention/drug type: gene-edited cellular immunotherapy (allogeneic CRISPR CAR T cells). Mechanism of action: donor T lymphocytes are engineered to express chimeric antigen receptors that bind tumor-associated antigens and trigger T-cell activation and cytotoxic killing, CRISPR genome editing is used to inactivate endogenous TCR (and potentially other loci) to enable off-the-shelf use and reduce graft-versus-host risk. Cells/pathways targeted: malignant cells expressing the CAR-targeted antigen, CAR signaling (CD3ζ/costimulatory domains), T-cell cytotoxic pathways (perforin/granzymes), and edited TCR pathways.